110 related articles for article (PubMed ID: 11686011)
1. Topoisomerase II inhibitors.
Toonen TR; Hande KR
Cancer Chemother Biol Response Modif; 2001; 19():129-47. PubMed ID: 11686011
[No Abstract] [Full Text] [Related]
2. Topoisomerase II inhibitors.
Clapp JM; Hande KR
Cancer Chemother Biol Response Modif; 2002; 20():125-49. PubMed ID: 12703203
[No Abstract] [Full Text] [Related]
3. DNA topoisomerase II poisons and inhibitors.
Capranico G; Giaccone G; D'Incalci M
Cancer Chemother Biol Response Modif; 1999; 18():125-43. PubMed ID: 10800480
[No Abstract] [Full Text] [Related]
4. DNA topoisomerase II poisons and inhibitors.
Capranico G; Giaccone G; Zunino F; Garattini S; D'Incalci M
Cancer Chemother Biol Response Modif; 1997; 17():114-31. PubMed ID: 9551211
[No Abstract] [Full Text] [Related]
5. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review).
Withoff S; De Jong S; De Vries EG; Mulder NH
Anticancer Res; 1996; 16(4A):1867-80. PubMed ID: 8712715
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
7. From DNA damage to G2 arrest: the many roles of topoisomerase II.
Larsen AK; Escargueil AE; Skladanowski A
Prog Cell Cycle Res; 2003; 5():295-300. PubMed ID: 14593724
[TBL] [Abstract][Full Text] [Related]
8. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase II as a target for anticancer chemotherapy.
Kaufmann SH; Hancock R
Acta Biochim Pol; 1995; 42(4):381-93. PubMed ID: 8852329
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of a mouse FM3A cell mutant resistant to topoisomerase II-inhibitor NC-190.
Samata K; Yamagishi T; Ichihara T; Nanaumi K; Ikeda T; Ikeya H; Kuraishi A; Nakaike S; Kashiwagi K; Igarashi K
Cancer Chemother Pharmacol; 2002 Nov; 50(5):367-72. PubMed ID: 12439594
[TBL] [Abstract][Full Text] [Related]
11. Effect of the anticancer drug oracin on mouse liver topoisomerases I and II.
Stuchlík S; Turna J; Miko M
J Pharm Pharmacol; 2005 May; 57(5):657-9. PubMed ID: 15901355
[TBL] [Abstract][Full Text] [Related]
12. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
[TBL] [Abstract][Full Text] [Related]
13. Function of topoisomerase II and the consequences of inhibition.
Davies SM
Med Pediatr Oncol Suppl; 1996; 1():12-9. PubMed ID: 8643041
[No Abstract] [Full Text] [Related]
14. Topoisomerase II inhibitors--teaching old dogs new tricks.
Sharma S
Cancer Invest; 2002; 20(4):596-7. PubMed ID: 12094555
[No Abstract] [Full Text] [Related]
15. [Resistance to cytostatic drugs].
Elonen E
Duodecim; 1998; 114(13):1319-28. PubMed ID: 11552258
[No Abstract] [Full Text] [Related]
16. [Topoisomerase II as a cellular receptor of various antineoplastic drugs].
Szmigiero L
Postepy Biochem; 1988; 34(3):147-52. PubMed ID: 2855749
[No Abstract] [Full Text] [Related]
17. Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl(2)(C(6)H(6))(dmso)].
Vashisht Gopal YN; Konuru N; Kondapi AK
Arch Biochem Biophys; 2002 May; 401(1):53-62. PubMed ID: 12054487
[TBL] [Abstract][Full Text] [Related]
18. Antitumor agents. Part 230: C4'-esters of GL-331 as cytotoxic agents and DNA topoisomerase II inhibitors.
Han S; Xiao Z; Bastow KF; Lee KH
Bioorg Med Chem Lett; 2004 Jun; 14(11):2979-82. PubMed ID: 15125972
[TBL] [Abstract][Full Text] [Related]
19. Synthetic lanostane-type triterpenoids as inhibitors of DNA topoisomerase II.
Wada S; Tanaka R
Bioorg Med Chem Lett; 2005 Jun; 15(12):2966-9. PubMed ID: 15914002
[TBL] [Abstract][Full Text] [Related]
20. Emerging DNA topisomerase inhibitors as anticancer drugs.
Denny WA
Expert Opin Emerg Drugs; 2004 May; 9(1):105-33. PubMed ID: 15155139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
